Building Rare Disease PSPs That Deliver in KSA

Most PSP frameworks developed for chronic disease categories assume a defined, diagnosed patient population reachable through primary or secondary care. Rare disease in Saudi Arabia breaks nearly every one of those assumptions.

Diagnosis is the first barrier. Many rare disease patients in KSA are diagnosed late — often after years of clinical misattribution. Epidermolysis Bullosa patients are frequently managed as dermatological cases for years before reaching a centre with rare disease expertise. SMA diagnoses that occur at or before symptom onset require newborn screening programs that are only now being systematically implemented at national scale.

The patient unit is the family, not the individual. Medical decisions — particularly for paediatric rare disease patients, who make up a significant portion of the KSA rare disease population — are made collectively by the family. PSPs designed around patient-individual engagement and consent will require cultural adaptation to function effectively.

Geography creates access gaps. Specialist rare disease centres are concentrated in Riyadh (King Faisal Specialist Hospital & Research Centre, King Abdulaziz Medical City), Jeddah, and Dammam. Patients from Najran, Jizan, Tabuk, and Al-Jouf regions may be hours from the nearest specialist — creating logistical barriers that the PSP must actively address.

1. Pre-Diagnosis Support and Patient Finding

A well-designed KSA rare disease PSP extends upstream of prescription to support patient identification. This includes disease awareness programs targeting paediatric specialists, neurologists, and metabolic disease units; clinical decision support resources; and collaboration with patient advocacy groups. The National Society for Rare Diseases (Nadir) plays an increasingly visible role in connecting families to specialist care, and partnering with Nadir-affiliated patient communities adds credibility and reach.

This upstream work is medical affairs territory and must be clearly distinguished from promotional activity in all planning and material review processes. The SFDA's guidance on disease awareness versus promotional communications is the relevant compliance reference.

2. Therapy Access Navigation

Many rare disease therapies in KSA require navigating a complex access pathway: SFDA registration, inclusion on the National Formulary, approval through individual hospital pharmacy and therapeutics committees, and in some cases Ministry of Health exceptional approval for unregistered therapies under the Named Patient Program framework.

An effective PSP should provide dedicated patient access support through a patient support coordinator (PSC) who understands both the clinical pathway and the administrative approval process, documentation support for access applications, and liaison with specialist pharmacies handling rare disease therapies.

3. Adherence and Infusion Support

For enzyme replacement therapies, biologics, and other infusion-based treatments, adherence is a question of logistics, nursing availability, and infusion centre capacity. Home infusion programs, where clinically appropriate, can significantly reduce burden on families in geographically remote regions. KSA's Vision 2030 healthcare transformation has accelerated investment in home health services.

PSP designs incorporating home infusion must address clinical eligibility criteria, nursing qualification requirements specific to the therapy, cold chain and storage protocols, and adverse event reporting pathways. Under SFDA pharmacovigilance requirements, PSP operators must have clear protocols for capturing and reporting adverse events from all care settings, including home.

4. Psychosocial and Family Support

Rare disease places extraordinary psychological and financial burden on Saudi families. A PSP that addresses only the biological dimensions of therapy adherence will underperform. Effective rare disease PSPs in KSA build in psychological support referral pathways, peer connection programs facilitated in partnership with patient advocacy organizations, and financial assistance information for families navigating co-pay burdens within the CCHI-covered private insurance framework.

These elements require careful governance to ensure the PSP maintains its character as a support service rather than a promotional vehicle.

5. Real-World Data and Outcomes Tracking

Rare disease PSPs generate rich longitudinal data on therapy outcomes, adherence patterns, health-related quality of life, and healthcare utilization. Under the Personal Data Protection Law (PDPL), any collection, storage, or use of patient health data in the context of a PSP must comply with consent, data minimization, and data security requirements. PSP operators should engage with PDPL-specialist legal counsel to ensure data governance frameworks are compliant before program launch.

Where data sharing agreements with treating institutions or the Saudi NHIC are established, rare disease PSP real-world data can contribute to national disease registries — supporting both patient outcomes and the Kingdom's Vision 2030 health data ambitions.

The consistent challenge rare disease teams face in KSA is securing internal investment for PSP programs operating at small patient scale. The counter-argument is straightforward: in rare disease, each patient represents a lifetime of therapy. The return on PSP investment is measured over patient lifetime value, not quarters. Moreover, the reputational capital a pharmaceutical brand builds within the rare disease specialist community translates directly into medical affairs access, publication collaboration, and clinical trial recruitment capability. In a small, closely networked rare disease specialist community, reputation compounds.

Spectra Solutions MEA has supported rare disease brands across the GCC in designing and executing patient support programs that address the full complexity of the KSA market — from patient identification through long-term adherence support. Contact us at service@spectra-mea.com to discuss how we can support your program.